SELLAS LIFE SCIENCES GROUP (SLS) Covered Calls

There are no covered calls available for SELLAS LIFE SCIENCES GROUP.

Born To Sell's covered call screener gives you full search capabilities so you can find stocks and ETFs that make good covered call candidates.

Want to make money with covered calls?  Sign Up For A Free Trial


Extended Business Description

SELLAS Life Sciences Group, Inc., a development-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications. The company's lead product candidate is galinpepimut-S, a cancer immunotherapeutic agent for the treatment of hematologic cancers and solid tumor indications, including acute myeloid leukemia, malignant pleural mesothelioma, multiple myeloma, ovarian cancer, immune combo, and chronic myelogenous leukemia. It also develops NEUVAX, which is in Phase II clinical trial for the treatment of breast cancer; and Anagrelide controlled release, which has completed various clinical trials for the treatment of thrombocythemia. The company has collaboration and license agreements with Memorial Sloan Kettering Cancer Center, Advaxis Immunotherapies, Merck & Co., Inc., National Cancer Institute, and the University of Texas M.D. Anderson Cancer Center. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York